Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$66.53
$62.58
$49.26
▼
$70.98
$12.88B0.242.14 million shs2.30 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$59.01
$55.07
$33.76
▼
$59.72
$14.62B0.422.16 million shs1.58 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$541.08
$529.90
$393.61
▼
$615.00
$12.50B-0.98241,034 shs177,162 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$11.94
$11.21
$6.28
▼
$12.48
$4.06B-0.17139,209 shs140,964 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.00%+2.88%+4.26%+17.65%+15.16%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+8.37%+9.14%+14.05%+55.78%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.00%+1.37%+6.09%+15.79%+24.99%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
0.00%+5.76%+3.65%+29.50%+31.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$66.53
$62.58
$49.26
▼
$70.98
$12.88B0.242.14 million shs2.30 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$59.01
$55.07
$33.76
▼
$59.72
$14.62B0.422.16 million shs1.58 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$541.08
$529.90
$393.61
▼
$615.00
$12.50B-0.98241,034 shs177,162 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$11.94
$11.21
$6.28
▼
$12.48
$4.06B-0.17139,209 shs140,964 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.00%+2.88%+4.26%+17.65%+15.16%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+8.37%+9.14%+14.05%+55.78%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.00%+1.37%+6.09%+15.79%+24.99%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
0.00%+5.76%+3.65%+29.50%+31.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.74
Moderate Buy$89.1734.04% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.35
Hold$50.07-15.16% Downside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$699.6429.30% Upside
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
2.86
Moderate Buy$20.4070.85% Upside

Current Analyst Ratings Breakdown

Latest TLX, EXEL, BMRN, and MDGL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Sell (D+)
9/2/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$20.00
9/1/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$88.00 ➝ $90.00
9/1/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/31/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$104.00 ➝ $105.00
8/31/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$59.00 ➝ $60.00
8/26/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$88.00
8/21/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Hold (C-)
8/20/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/20/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$22.00
8/19/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$98.00
(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$3.22B4.00$2.85 per share23.32$31.68 per share2.10
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.32B6.30$3.03 per share19.49$8.06 per share7.32
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M13.04N/AN/A$26.54 per share20.39
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$803.79M5.05$0.04 per share283.18$1.23 per share9.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$348.90M$0.37179.8112.210.482.14%5.32%3.69%10/26/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1818.5615.861.7635.33%42.17%31.76%11/3/2026 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A97.49N/A-25.32%-56.65%-25.53%11/3/2026 (Estimated)
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-$7.12MN/AN/A199.00N/AN/AN/AN/AN/A

Latest TLX, EXEL, BMRN, and MDGL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.95$1.20+$0.25$0.23$932.03 million$989.71 million
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.56
2.39
1.32
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1.16
2.01
1.85

Institutional Ownership

CompanyInstitutional Ownership
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.68%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,221193.57 million192.26 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9023.10 million19.04 millionOptionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1,184339.78 millionN/AN/A

Recent News About These Companies

TLX stock clocks 5% gain this week ahead of FDA decision on brain cancer imaging agent
September 4 at 7:44 PM  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/tlx-stock-clocks-5-gain-this-week-ahead-of-fda-decision-on-brain-cancer-imaging-agent/ar-AA2bAHHK
Telix Pharmaceuticals Limited (TLX)
September 4 at 9:42 AM  |  finance.yahoo.comhttps://finance.yahoo.com/quote/TLX/news/
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - Here's What Happened
September 4 at 4:00 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003200
HC Wainwright Reaffirms "Buy" Rating for Telix Pharmaceuticals (NASDAQ:TLX)
September 4 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31001694
Telix shares are up 98%: Is there more upside to come?
September 3, 2026  |  msn.comhttps://www.msn.com/en-au/money/top-stocks/telix-shares-are-up-98-is-there-more-upside-to-come/ar-AA2bsMN7
Telix Pharmaceuticals Limited (NASDAQ:TLX) Given Average Recommendation of "Moderate Buy" by Brokerages
September 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31000143
Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Recommendation of "Moderate Buy" from Analysts
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-telix-pharmaceuticals-limited-nasdaq-tlx-receives-average-recommendation-of-moderate-buy-from-analysts-2026-09-03/
Telix Pharmaceuticals shares rise 5.3% as analyst highlights BiPASS trial and FDA pathway
September 2, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/telix-pharmaceuticals-shares-rise-53-as-analyst-highlights-bipass-trial-and-fda-pathway/ar-AA2bqKRm
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - What's Next?
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-telix-pharmaceuticals-nasdaq-tlx-shares-gap-up-whats-next-2026-09-02/
Telix Pharmaceuticals' (TLX) Buy Rating Reaffirmed at HC Wainwright
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-telix-pharmaceuticals-tlx-buy-rating-reaffirmed-at-hc-wainwright-2026-09-02/
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354739/0/en/telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway.html
Telix Appoints Gill As Board Chairman
September 1, 2026  |  rttnews.comhttps://www.rttnews.com/3687297/telix-appoints-gill-as-board-chairman.aspx
Telix Appoints David Gill as Chair
August 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/31/3353743/0/en/telix-appoints-david-gill-as-chair.html
Telix Pharmaceuticals (NASDAQ:TLX) Stock Price Down 4.5% - Time to Sell?
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-telix-pharmaceuticals-nasdaq-tlx-stock-price-down-45-time-to-sell-2026-08-26/
Telix Pharmaceuticals: Execution Is The Name Of The Game Here
August 24, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4939766-telix-pharmaceuticals-execution-is-the-name-of-the-game-here
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What Happened
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-nasdaqtlx-shares-gap-down-heres-what-happened-2026-08-21/
HotCopper highlights: Zip dominates investor attention as Telix, Liontown and American Tungsten trend
August 21, 2026  |  msn.comhttps://www.msn.com/en-au/money/top-stocks/hotcopper-highlights-zip-dominates-investor-attention-as-telix-liontown-and-american-tungsten-trend/ar-AA2aC3f9
Why were Telix shares just downgraded?
August 20, 2026  |  fool.com.auhttps://www.fool.com.au/2026/08/21/why-were-telix-shares-just-downgraded/
Telix Pharmaceuticals Limited (TLX) Stock: EBITDA Surges 146% as Revenue Hits $477M 
August 20, 2026  |  blockonomi.comhttps://blockonomi.com/telix-pharmaceuticals-limited-tlx-stock-ebitda-surges-146-as-revenue-hits-477m/
Telix Pharmaceuticals Limited: Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
August 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69361480-telix-pharmaceuticals-limited-telix-2026-half-year-results-strong-commercial-execution-and-momentum-in-late-stage-pipeline-399.htm
Telix Pharmaceuticals (NASDAQ:TLX) Receives "Outperform" Rating from Wedbush
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-nasdaqtlx-receives-outperform-rating-from-wedbush-2026-08-20/

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$66.53 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$59.01 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$541.08 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$11.94 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas